These studies elucidate that the frequently reported reversible resistance seen in treated tumour populations such as BRAF mutant melanoma or EGFR mutant NSCLC may be an attribute of a common resistance mechanism achieved through phenotypic switching and alteration of epigenetic landscapes. This evidence concerns the gene BRAF and non-small cell lung carcinoma.